JP2010504908A5 - - Google Patents

Download PDF

Info

Publication number
JP2010504908A5
JP2010504908A5 JP2009520765A JP2009520765A JP2010504908A5 JP 2010504908 A5 JP2010504908 A5 JP 2010504908A5 JP 2009520765 A JP2009520765 A JP 2009520765A JP 2009520765 A JP2009520765 A JP 2009520765A JP 2010504908 A5 JP2010504908 A5 JP 2010504908A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
group
alkyl
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2009520765A
Other languages
English (en)
Japanese (ja)
Other versions
JP5266219B2 (ja
JP2010504908A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/015808 external-priority patent/WO2008010934A2/en
Publication of JP2010504908A publication Critical patent/JP2010504908A/ja
Publication of JP2010504908A5 publication Critical patent/JP2010504908A5/ja
Application granted granted Critical
Publication of JP5266219B2 publication Critical patent/JP5266219B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2009520765A 2006-07-14 2007-07-10 トリアゾリルフェニルベンゼンスルホンアミド類 Active JP5266219B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US83104206P 2006-07-14 2006-07-14
US60/831,042 2006-07-14
US94583907P 2007-06-22 2007-06-22
US60/945,839 2007-06-22
PCT/US2007/015808 WO2008010934A2 (en) 2006-07-14 2007-07-10 Triazolyl phenyl benzenesulfonamides

Publications (3)

Publication Number Publication Date
JP2010504908A JP2010504908A (ja) 2010-02-18
JP2010504908A5 true JP2010504908A5 (enExample) 2012-05-24
JP5266219B2 JP5266219B2 (ja) 2013-08-21

Family

ID=38896161

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009520765A Active JP5266219B2 (ja) 2006-07-14 2007-07-10 トリアゾリルフェニルベンゼンスルホンアミド類

Country Status (21)

Country Link
EP (1) EP2046762B1 (enExample)
JP (1) JP5266219B2 (enExample)
KR (1) KR101433392B1 (enExample)
AT (1) ATE498615T1 (enExample)
AU (1) AU2007275873B2 (enExample)
BR (1) BRPI0714407A2 (enExample)
CA (1) CA2657776C (enExample)
CO (1) CO6180465A2 (enExample)
DE (1) DE602007012552D1 (enExample)
DK (1) DK2046762T3 (enExample)
EA (1) EA015710B1 (enExample)
IL (1) IL196409A (enExample)
MA (1) MA30690B1 (enExample)
MX (1) MX2009000395A (enExample)
NO (1) NO341949B1 (enExample)
NZ (1) NZ574759A (enExample)
PL (1) PL2046762T3 (enExample)
PT (1) PT2046762E (enExample)
UA (1) UA98304C2 (enExample)
WO (1) WO2008010934A2 (enExample)
ZA (1) ZA200900281B (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE496905T1 (de) 2006-07-14 2011-02-15 Chemocentryx Inc Triazolyl-pyridyl-benzolsulfonamide als ccr2- oder ccr9-modulatoren zur behandlung von atherosklerose
CN101679319B (zh) 2007-02-08 2014-07-09 辛塔医药品有限公司 用于治疗增生性病症如癌症的三唑类化合物
TWI490214B (zh) * 2008-05-30 2015-07-01 艾德克 上野股份有限公司 苯或噻吩衍生物及該等作為vap-1抑制劑之用途
MX2011000051A (es) * 2008-07-07 2011-07-28 Fasgen Inc Nuevos compuestos, composiciones farmaceuticas que contienen los mismos, metodos para usar los mismos, y metodos para preparar los mismos.
WO2011082271A2 (en) 2009-12-30 2011-07-07 Arqule, Inc. Substituted triazolo-pyrimidine compounds
JP5998152B2 (ja) * 2011-01-25 2016-09-28 ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン Bcl−2/bcl−xl阻害剤およびそれを使用する治療方法
WO2013016156A1 (en) * 2011-07-22 2013-01-31 Glaxo Group Limited Polymorphic forms of the sodium salt of 4-tert- butyl -n-[4-chloro-2-(1-oxy-pyridine-4-carbonyl)-phenyl]-benzene sulfonamide
MX350269B (es) * 2011-07-22 2017-08-31 Chemocentryx Inc Una forma cristalina de la sal de sodio de 4-ter-butil-n-[4-cloro- 2-(1-oxi-piridina-4-carbonil)-fenil]-bencensulfonamida.
MX2014000659A (es) * 2011-07-22 2014-07-09 Chemocentrix Inc Formas polimorficas de la sal de sodio de 4-ter-butil-[4-cloro-2-( 1-oxi-piridina-4-carbonil)-fenil]-bencensulfonamida.
EP2771484A1 (en) 2011-10-28 2014-09-03 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
RU2627268C2 (ru) * 2012-02-29 2017-08-04 Хемоцентрикс, Инк. Аза-арил-1Н-пиразол-1-ил-сульфонамиды
DK3345899T3 (da) * 2012-03-01 2020-05-11 Allergan Inc Benzofuran-2-sulfonamidderivater som kemokinreceptormodulatorer
EA029826B1 (ru) * 2013-12-02 2018-05-31 Кемосентрикс, Инк. Соединения против ccr6
US20170002011A1 (en) 2013-12-23 2017-01-05 Norgine B.V. Benzene sulfonamides as ccr9 inhibitors
WO2015097121A1 (en) 2013-12-23 2015-07-02 Norgine B.V. Compounds useful as ccr9 modulators
US10000458B2 (en) * 2016-03-31 2018-06-19 Sumitomo Chemical Company, Limited Production method of 1, 2, 4-triazole compound
CA3136279A1 (en) 2019-05-09 2020-11-12 Grey Wolf Therapeutics Limited Phenyl-sulfamoyl.benzoyc acids as erap1 modulators
US11872217B2 (en) 2019-07-10 2024-01-16 Chemocentryx, Inc. Indanes as PD-L1 inhibitors
US11713307B2 (en) 2019-10-16 2023-08-01 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
CR20220216A (es) 2019-10-16 2023-01-09 Chemocentryx Inc Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
CN115477626B (zh) * 2021-06-16 2024-08-02 上海璃道医药科技有限公司 N-取代苯基磺酰胺类化合物及其用途
JP2024534799A (ja) * 2021-08-20 2024-09-26 エナンタ ファーマシューティカルズ インコーポレイテッド 17-ベータ-ヒドロキシステロイドデヒドロゲナーゼ13型阻害剤及びその使用方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
US6159686A (en) 1992-09-14 2000-12-12 Sri International Up-converting reporters for biological and other assays
US5514555A (en) 1993-03-12 1996-05-07 Center For Blood Research, Inc. Assays and therapeutic methods based on lymphocyte chemoattractants
US6322901B1 (en) 1997-11-13 2001-11-27 Massachusetts Institute Of Technology Highly luminescent color-selective nano-crystalline materials
US6207392B1 (en) 1997-11-25 2001-03-27 The Regents Of The University Of California Semiconductor nanocrystal probes for biological applications and process for making and using such probes
US5990479A (en) 1997-11-25 1999-11-23 Regents Of The University Of California Organo Luminescent semiconductor nanocrystal probes for biological applications and process for making and using such probes
US6306610B1 (en) 1998-09-18 2001-10-23 Massachusetts Institute Of Technology Biological applications of quantum dots
US6251303B1 (en) 1998-09-18 2001-06-26 Massachusetts Institute Of Technology Water-soluble fluorescent nanocrystals
US6326144B1 (en) 1998-09-18 2001-12-04 Massachusetts Institute Of Technology Biological applications of quantum dots
US6294192B1 (en) 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
US7468253B2 (en) 2001-06-07 2008-12-23 Chemocentryx, Inc. Method for multiple chemokine receptor screening for antagonists using RAM assay
DK1417488T3 (da) 2001-06-07 2007-03-05 Chemocentryx Inc Cellemigrasionsassay
EP2399903A1 (en) 2002-05-24 2011-12-28 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
AU2003298661B2 (en) * 2002-11-18 2007-05-10 Chemocentryx, Inc. Aryl sulfonamides
US7420055B2 (en) 2002-11-18 2008-09-02 Chemocentryx, Inc. Aryl sulfonamides
JO2397B1 (en) * 2002-12-20 2007-06-17 ميرك شارب اند دوم كوربوريشن Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors
WO2005004810A2 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
US20090048301A1 (en) * 2003-07-09 2009-02-19 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
CA2566387A1 (en) * 2004-05-12 2005-12-01 Chemocentryx, Inc. Aryl sulfonamides as chemokine receptor ccr9 antagonists
US9715915B2 (en) 2014-10-30 2017-07-25 Samsung Electronics Co., Ltd. Magneto-resistive devices including a free layer having different magnetic properties during operations

Similar Documents

Publication Publication Date Title
JP2010501534A5 (enExample)
JP2009535462A5 (enExample)
JP2010501478A5 (enExample)
JP2019104748A5 (enExample)
JP2010519270A5 (enExample)
JP2009515988A5 (enExample)
JP2012092103A5 (enExample)
JP2010520851A5 (enExample)
JP2008500997A5 (enExample)
JP2010536766A5 (enExample)
JP2014500870A5 (enExample)
JP2015143283A5 (enExample)
JP2011037841A5 (enExample)
JP2008510770A5 (enExample)
JP2013510178A5 (enExample)
JP2009511508A5 (enExample)
JP2011016798A5 (enExample)
JP2009500423A5 (enExample)
JP2012509265A5 (enExample)
JP2015510508A5 (enExample)
JP2010521516A5 (enExample)
JP2010534246A5 (enExample)
JP2012511558A5 (enExample)
JP2012503653A5 (enExample)
JP2011528662A5 (enExample)